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ABSTRACT 
 
Aim: To investigate the impact of histology on outcome in advanced 
oesophageal cancer treated with first-line fluoropyrimidine-based 
chemotherapy. 
Patients and Methods: Individual patient data were pooled from three 
randomised phase III trials of fluoropyrimidine-based chemotherapy +/- 
platinum/anthracycline in patients with advanced, untreated 
gastroesophageal adenocarcinoma or squamous cell carcinoma (SCC) 
randomised between 1994 and 2005. The primary endpoint was overall 
survival of oesophageal cancer patients according to histology. Secondary 
endpoints were response rates and a toxicity composite endpoint. 
Results: Of the total 1836 randomised patients, 973 patients (53%) were 
eligible (707 patients with gastric cancer were excluded), 841 (86%) had 
adenocarcinoma and 132 (14%) had SCC. There was no significant difference 
in survival between patients with adenocarcinoma and SCC, with median 
overall survivals of 9.5 versus 7.6 months (HR 0.85, 95% CI 0.70-1.03, p=0.09) 
and one-year survivals of 38.8% versus 28.2% respectively. The overall 
response rate to chemotherapy was 44% for adenocarcinoma versus 33% for 
SCC (p=0.01). There was no difference in the frequency of the toxicity 
composite endpoint between the two groups.   
Conclusions: There was no significant difference in survival between 
adenocarcinoma and SCC in patients with advanced oesophageal cancer 
treated with fluoropyrimidine-based chemotherapy despite a trend for worse 
survival and less chemo-sensitivity in SCC. Tolerance to treatment was 
similar in both groups. This analysis highlights the unmet need for SCC-
specific studies in advanced oesophageal cancer and will aid in the design of 
future trials of targeted agents. 
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CORE TIP: 
 
There is a lack of published data on differential treatment response according 
to histology in oesophageal cancer. This paper shows improved response 
rates with first-line chemotherapy and a trend towards improved survival in 
adenocarcinoma compared to SCC. It is increasingly recognised that these 
histological subtypes represent discrete disease entities with divergent 
treatment pathways in both the early stage and advanced settings. Novel 
treatments in SCC remain sparse and there are few dedicated trials in this 
subtype. This data highlights the poor outcomes seen with chemotherapy 
alone and the need for further research, particularly for SCC.  
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INTRODUCTION 
 
Oesophageal cancer is the eighth most common malignancy worldwide with 
an estimated 456 000 new cases and 400 000 deaths worldwide in 2012, 
ranking it the sixth most common cause of cancer-related deaths[1].  Despite 
recent advances in genetic and molecular characterisation and the 
development of novel targeted agents survival rates for oesophageal 
carcinoma have changed little for many decades, and outcomes for advanced 
disease remain poor. Worldwide, squamous cell carcinoma (SCC) is the 
predominant histological subtype however in North America and Northern 
Europe the incidence of oesophageal adenocarcinoma has increased in the last 
20 years whereas that of SCC has decreased[2, 3]. This is likely to reflect the 
distinct aetiological factors implicated in the development of the two diseases. 
SCC is strongly correlated with excessive alcohol consumption, cigarette 
smoking and poor socioeconomic status whereas adenocarcinoma is 
associated with obesity and gastroesophageal reflux disease (GORD)[3-6]. Thus 
the rise in adenocarcinoma may be in part due to changing lifestyle factors in 
Western populations[3]. Genomic technology has been applied to both gastric 
and oesophageal cancer in an effort to improve understanding and 
stratification on a genetic and molecular level, with emerging differences in 
the genetic landscape between the two histological subtypes suggesting a 
need for more tailored therapeutic strategies[7, 8]. Historically however 
treatment patterns for both subtypes have been similar, with many clinical 
trials evaluating chemotherapy conducted since the mid-1990s including 
patients with gastric, oesophageal, or oesophagogastric junction (OGJ) cancer, 
regardless of histology. Similarly, studies in early stage oesophageal cancer 
often include both histological subtypes, such as the recent CROSS trial 
evaluating neoadjuvant chemo-radiation. This identified disparities in 
outcome according to histology, with a statistically significant overall survival 
benefit seen only in the smaller SCC cohort[9].  
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In the advanced disease setting cisplatin/ fluorouracil with the possible 
addition of a third drug- either epirubicin or a taxane- is commonly used as a 
first-line chemotherapy, and second-line agents include irinotecan, docetaxel 
and paclitaxel[10] [11].  More recently treatment patterns have diverged, with 
the introduction of novel molecularly-targeted therapy for gastroesophageal 
adenocarcinomas. Notably effective therapies targeting HER2 (trastuzumab) 
and the vascular endothelial growth factor receptor 2 (ramucirumab) are 
applicable only to adenocarcinomas[12-14].  
 
Three randomised phase III studies of fluoropyrimidine-based combination 
chemotherapy have been published in patients with advanced 
gastroesophageal cancer including oesophageal SCC and 
adenocarcinoma[10],[15],[16],. In multivariate Cox regression analysis histology 
was not identified as a variable impacting on survival, however patients with 
SCC accounted for less than 10% of the patients in each trial. Although SCC 
normally represent a small minority of patients enrolled on most clinical trials 
it is not clear what influence histologic subtype exerts on response rate or 
survival duration in patients treated with cytotoxic chemotherapy regimens 
for metastatic disease, and SCC has been associated with both worse, better or 
similar outcomes to adenocarcinoma[17-19]. The distinct epidemiological, 
genetic and molecular characteristics of SCC as compared to adenocarcinoma 
could potentially influence response to therapies administered in the 
advanced disease setting. In this pooled analysis of the three randomised 
phase III studies which included patients with both advanced oesophageal 
SCC and adenocarcinoma, we aimed to evaluate whether there was a 
differential treatment effect according to histology.   
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PATIENTS and METHODS 
Patients and Treatments 
Between 1994 and 2005, 1836 patients were randomised predominantly from 
the UK in three multi-centre randomised controlled trials of 
fluoropyrimidine-based chemotherapy in patients with untreated locally 
advanced or metastatic carcinoma of oesophagus, OGJ, or stomach[10, 15, 16]. 
Similar eligibility criteria were applied in the three trials; patients had 
histologically confirmed inoperable adenocarcinoma, squamous cell 
carcinoma or undifferentiated carcinoma of the oesophagus, OGJ or stomach, 
adequate haematological, renal and hepatic function and an Eastern Co-
operative Oncology Group performance status (PS) of 0-2.  Written informed 
consent was obtained from all patients and all three studies were approved by 
the Scientific and Research Ethics Committees of the participating institutions.   
 
The first study randomised 580 patients between 1995 and 1998 to treatment 
with ECF (epirubicin 50 mg/m2 intravenously [IV] and cisplatin 60 mg/m2 IV 
infusion with hydration on day 1 plus 5-FU 200 mg/m2/day by protracted 
venous infusion [PVI]) or MCF (mitomycin C [MMC] 7 mg/m2 on day 1 every 
six weeks, cisplatin 50 mg/m2 IV day 1 and PVI-5-FU 300 mg/m2/day)[15].  
The second study randomised 254 patients between 1994 and 2001 to PVI 5-
FU (300 mg/m2/day) or the same dose of PVI 5-FU plus MMC (7 mg/m2 
every six weeks)[16].  The third study conducted randomised 1,002 patients 
between 2000 and 2005 to ECF, ECX (X denotes capecitabine given at a dose of 
625 mg/m2 twice a day continuously), EOF (O denotes oxaliplatin 130 mg/m2 
on day 1 every three weeks replacing cisplatin) and EOX[10].  
 
A maximum of 8 cycles of chemotherapy (24 weeks) with response 
assessment computed tomography (CT) scans at 12 and 24 weeks was 
stipulated in the three study protocols. Overall survival (OS) was the primary 
outcome measure in these trials and toxicity data was recorded at each 
treatment visit every three weeks.  
8 
 
 
Only eligible patients with squamous carcinoma or 
oesophageal/oesophagogastric junctional (OGJ) adenocarcinoma who 
received at least one dose of chemotherapy were included in this analysis 
which was based on individual patient data from these trials. 
 
Statistical Analysis  
OS was the primary endpoint of this pooled analysis and was calculated from 
the date of randomisation until death from any cause, or censored at the date 
of last follow-up for surviving patients according to the Kaplan-Meier 
method. Survival analyses were performed on the eligible population and 
compared between patients with SCC and adenocarcinoma using the log rank 
test. Multivariate survival analysis was performed using Cox proportional 
hazard model and stratified for treatment centres.  The following factors were 
included: histology, gender, primary site (oesophagus vs. OGJ), liver or 
peritoneal metastases (presence vs. absence), serum alkaline phosphatase 
(<100 vs. ≥100U/l) and performance status (0-1 vs. 2) based on previously-
identified prognostic factors in advanced OG cancer[20, 21], as well as treatment 
arm and trial.  
 
Objective response rates between SCC and adenocarcinoma were compared 
using Chi Square test.  A chemotherapy-specific toxicity composite endpoint 
(TCE) was constructed as a surrogate for undesirable cyctotoxic-related 
toxicities.  TCE was defined as the first occurrence of grade 3 or 4 diarrhoea, 
neutropenia, febrile neutropenia, fever, infection, nausea & vomiting or grade 
≥2 renal or neurotoxicity.  TCE was compared between the two histological 
subtypes using Chi Square test.  Time to TCE was compared between SCC 
and adenocarcinoma using log rank test. 
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Two-sided p value of less than 0.05 were considered significant for the overall 
survival endpoint, and 95% confidence intervals (CI) quoted. Analyses were 
performed using SPSS package version 23 (SPSS Inc, Chicago IL).   
 
RESULTS 
Patient Characteristics 
Of the 1836 patients randomised to the three trials, 973 patients (53%) were 
eligible for this pooled analysis as indicated in Figure 1. 707 of the 1836 
patients (39%) were excluded due to the primary tumour origin being gastric.  
Of the 973 eligible patients 841 (86%) had adenocarcinoma and 132 (14%) had 
SCC. Baseline patient characteristics are shown in Table 1. These were broadly 
balanced between the two histological sub-types except that predictably a 
greater proportion of adenocarcinoma occurred at the OGJ with metastases to 
the liver/peritoneum, and there were more males with adenocarcinoma.  
 
Survival 
At the time of the data cut-off, 863 of the 973 patients (88%) had died and the 
median follow-up for surviving patients was 19 months. The median survival 
for the whole cohort of 973 eligible patients was 9.4 months (95% CI 8.82-9.99). 
One year survival was 37.3% (95% CI 37.27-37.33) and 2 year survival was 
13.5% (95% CI 13.48 - 13.52).  There was no significant difference in survival   
between patients with adenocarcinoma and SCC, with median OS of 9.5 
versus 7.6 months (HR 0.85, 95% CI 0.70-1.03, p=0.09), although the curves 
did appear to separate between 6 months to 2 years suggestive of a poorer 
survival for SCC during this period (Figure 2A). One and two year survival 
figures for adenocarcinoma were 38.8% (95% CI 38.77-38.83) and 13.6% (95% 
CI 13.57-13.63) respectively and for SCC were 28.2% (95% CI 28.12-28.28) and 
12.3% (95% CI 12.24-12.36). When considering only ‘true’ oesophageal cancer 
patients only and excluding those with junctional tumours, there was again 
no significant difference in survival between patients with adenocarcinoma 
(n=438) and SCC (n=117), with median OS of 9.5 versus 7.7 months (HR 0.91, 
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95% CI 0.73-1.13, p=0.38) (Figure 2B).  In multivariate analysis, previously 
identified known prognostic factors of performance status, liver/peritoneal 
metastases and alkaline phosphatase were all significant.  Histology and site 
of primary tumour were not shown to be significant prognostic factors. For 
effect of treatment received there was a significant association of treatment 
within trial 216- which did not incorporate a platinum component into either 
treatment arm- with poorer outcome (Table 2).  
 
Response and Toxicity 
The objective response rate to chemotherapy (Table 3) was significantly 
higher for patients with adenocarcinoma compared to SCC (44% vs. 33%, 
p=0.01). A greater proportion of patients with SCC compared to 
adenocarcinoma progressed during chemotherapy (29% vs. 19%, p= 0.01) and 
the proportion of patients with stable disease was similar for both histological 
subtypes.  There was no difference in the proportion of patients experiencing 
the toxicity composite endpoint (TCE) for adenocarcinoma as compared to 
SCC (45% versus 44%, p=0.77) (Table 3).  Similarly there was no difference in 
the time to development of TCE (Figure 3) between the histological subtypes 
(HR 0.98, 95% CI  0.74–1.29, p= 0.9). 
 
DISCUSSION 
This study represents the largest pooled analysis of differential chemotherapy 
effects in patients with advanced oesophageal adenocarcinoma and SCC 
undergoing fluoropyrimidine-based chemotherapy in randomised phase III 
controlled trials with mature survival data. All three analysed trials 
incorporated a fluoropyrimidine in each treatment arm, and two of the trials 
included a platinum agent in each arm.  In this pooled analysis there was no 
significant difference in overall survival between patients with 
adenocarcinoma compared to those with SCC with median overall survivals 
of 9.5 versus 7.6 months (HR 0.85, p= 0.09) respectively. A possible limitation 
of interpretation of this data is the imbalanced distribution of histological 
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subtype between oesophageal and OGJ cancers. As expected, the proportion 
of SCC histology was higher in the oesophageal only group as compared to 
the total cohort of oesophageal and OGJ patients (21% versus 14%).   A further 
analysis excluding OGJ patients however also did not show a significant 
difference in median OS between adenocarcinoma and SCC (9.5 versus 7.7 
months, HR 0.91, p=0.38). Histology and site of primary tumour were not 
shown to be predictors of survival in multivariate analysis, consistent with 
previously reported prognostic variables in oesophageal and gastric cancer 
based on smaller analyses[20, 22, 23]. The survival curves did appear to separate 
between 6 months and 2 years, with SCC patients appearing to have worse 
survival during this period, but the curves then overlapped from two years 
onwards. Lack of a statistically significant difference in survival in the 
presence of a trend could reflect that this pooled analysis remains 
underpowered. Although the potential for heterogeneity may confound 
interpretation of data from pooled analyses, the eligibility criteria for these 
three trials were similar, individual patient data were used to strengthen the 
analysis, treatment arms and trials were incorporated in the multivariate 
analysis and survival outcomes from ECF, evaluated in the two largest 
trials[10, 15], were consistent. Inclusion of patients with advanced SCC in these 
studies was controversial in terms of potentially creating a heterogeneous 
study population however based on the current analysis survival outcomes 
with standard chemotherapy are not significantly different with SCC 
compared to adenocarcinoma, although there may be a trend towards worse 
survival. The only differential treatment effect noted was a significant 
difference in objective response rates between adenocarcinoma and SCC (44% 
vs. 33% respectively).  A greater proportion of SCC patients also progressed 
during treatment (29% vs. 19%), suggesting that oesophageal SCC may be less 
chemo-sensitive than adenocarcinoma.   
 
There was no difference in time to development of TCE or of the proportion 
of patients with TCE between the two histological sub-types. A difference 
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might have been expected given the association of co-morbid conditions with 
SCC. However, within clinical trials there may be selection bias favouring 
inclusion of fitter patients (patients with a performance status of 2 comprised 
only 15% of the pooled patient population in this analysis). Although this 
does potentially limit extrapolation of the results of this analysis to patients 
with SCC in the general population this would apply to most randomised 
controlled trials in this disease.  
 
Application of genomic technology is revealing increasing differences 
between the histological subtypes of oesophageal cancer on a genetic and 
molecular level. In an analysis performed by the Cancer Genome Atlas, four 
gastric cancer subtypes have been proposed: tumours positive for Epstein-
Barr virus (EBV), microsatellite unstable tumours (MSI), genomically stable 
(GS) tumours and tumours with chromosomal instability (CIN)[24]. Each 
subtype was found throughout the stomach, but CIN tumours showed 
elevated frequency in the OGJ and cardia. In CIN tumours genomic 
amplifications of receptor tyrosine kinases such as VEGFA and cell cycle 
mediators such as CCND1 and CDK6 with potentially relevant clinical 
implications were found with increased frequency. Specific to oesophageal 
adenocarcinomas, a sequencing study of 149 tumours by a US group 
published in Nature Medicine in 2013 confirmed recurrent mutations in 
known cancer-driving genes including TP53, CDKN2A, SMAD4, ARID1A and 
PIK3CA[25]. Similarly, a number of recent studies have applied NGS to the 
study of oesophageal SCC, demonstrating recurrent mutations in known 
oncogenic drivers including TP53, NOTCH1, PIK3CA and FAT1, as well as 
amplifications in CCND1 and CDKN2A[26]. The cell cycle regulation pathway 
is one of the most consistently altered in oesophageal SCC, where mutations 
are observed at a high frequency and are associated with poor prognosis and 
metastasis[27] [28]. A recent study has compared the genomic profiles of 71 SCC 
and 231 oesophageal adenocarcinomas, focusing on the identification of 
therapeutically relevant genomic alterations in both groups[8]. Similarly high 
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frequencies of clinically relevant genomic alterations were found in both 
histological subtypes; however the profiles of genomic alterations in the two 
diseases differed substantially. KRAS and HER2 were more frequently altered 
in adenocarcinoma, while MTOR pathway genes (PIK3CA, PTEN) and 
NOTCH1 were more frequently altered in SCC. Exploitation of the molecular 
differences between the two histological sub-types may help direct optimal 
application of targeted therapies in this disease.  
 
Although our data is historical, the chemotherapy landscape for oesophageal 
cancers has not changed significantly in the intervening years. Targeted 
treatments for oesophageal adenocarcinomas are now in routine clinical use 
and starting to provide tangible improvement to patient outcomes, however 
there remains a relative lack of both applied research and effective treatments 
for advanced SCC. Given small patient numbers and apparently declining 
incidence, further randomised SCC-specific phase III trials of systemic 
therapy in advanced oesophageal cancer in Western populations will be 
challenging. Future improvements in outcome are likely to come from smaller 
studies investigating cohorts of patients enriched for discrete genetic 
aberrations, or from the use of combination immunotherapeutic approaches. 
Optimising the design of such studies using appropriate chemotherapies as 
either comparators or backbones to newer investigative agents requires an 
understanding of differential effectiveness and toxicity of standard 
chemotherapy regimes. This analysis demonstrated no significant difference 
in survival or tolerance to chemotherapy between patients with 
adenocarcinoma or SCC. Given the poor outcomes seen with chemotherapy it 
reinforces the need for SCC-specific trials in advanced oesophageal cancer. 
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COMMENTS 
 
1. Background 
The two main histological subtypes of oesophageal cancer, adenocarcinoma 
and SCC, are increasingly regarded as discrete disease entities with divergent 
treatment pathways. This is reflected in recent international guidance from 
both the National Comprehensive Cancer Institute and European Society of 
Medical Oncology, which recommend differing treatment approaches in early 
stage and, to a lesser extent, late stage disease dependent on histology[29][30].  
 
2. Research frontiers 
Although the chemotherapy landscape for advanced oesophageal cancer has 
not changed in recent years, improved understanding of the molecular and 
genomic underpinnings of the disease have led to tangible improvements in 
outcome, with effective biological targeted agents such as trastuzumab and 
ramucirumab making a tangible difference to patient outcomes. The clinical 
application of such targeted agents has so far however been limited to the 
adenocarcinoma subtype.  Emerging data on the use of immunotherapy 
suggests that it will also play a role in this condition. Recent preliminary data 
from trials of immunotherapy agents such as the KEYNOTE 028 study 
evaluating use of the anti-PD1 agent pembrolizumab in advanced 
oesophageal cancer have reported promising signal in both adenocarcinoma 
and SCC patients, and studies of immunotherapy in both histological 
subtypes are ongoing[31].  Although SCC remains a significant health problem 
on a global scale, incidence in Western populations is declining and further 
large scale randomised trials restricted to this subtype are unlikely. 
 
3. Innovations and breakthroughs  
There is a lack of randomised data on differential chemotherapy response 
according to histology in oesophageal cancer. This paper shows that 
adenocarcinomas had a significantly higher response rate to first line 
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fluoropyrimidine-based chemotherapy than SCC.  Although there was also a 
trend towards improved survival outcomes this did not reach statistical 
significance. This data confirms the generally poor outcomes seen with 
chemotherapy in advanced oesophageal cancer and suggests that 
oesophageal SCC may be a less chemotherapy-sensitive disease than 
adenocarcinoma.    
 
4. Applications 
Given the now established role of targeted agents in the management of 
advanced oesophageal adenocarcinoma and an emerging potential role for 
immunotherapeutic approaches it is possible that treatment pathways for the 
two subtypes will further diverge. Improvements in outcome are likely to 
come from smaller studies investigating targeted agents or combination 
immunotherapeutic approaches. Optimising the design of such studies using 
appropriate chemotherapies as either comparators or backbones to newer 
investigative agents requires knowledge of the differential effectiveness and 
toxicity of chemotherapy. 
 
 
16 
 
Table 1:  Patient Characteristics  
 Adeno 
 
SCC Total 
Number of Patients 
 
841 132 973 
Median age (range) 
 
62 (22-84) 60 (37-77) 61 (22-84) 
Gender 
    Male 
    Female 
 
 
730 (87%) 
111 (13%) 
 
95 (72%) 
37 (28%) 
 
825 (85%) 
148 (15%) 
Performance Status* 
    0 
    1 
    2 
 
223 (27%) 
489 (58%) 
127 (15%) 
 
 
33 (25%) 
75 (57%) 
23 (18%) 
 
256 (26%) 
564 (58%) 
150 (15%) 
 
Sub-site 
    Oesophagus 
    GOJ 
     
 
438 (52%) 
403 (48%) 
 
 
117 (89%) 
15 (11%) 
 
555 (57%) 
418 (43%) 
Extent of Disease** 
    Locally Advanced 
    Metastatic 
 
 
219 (26%) 
622 (74%) 
 
36 (27%) 
95 (72%) 
 
255 (26%) 
717 (74%) 
Location of Metastases 
    Liver 
    Peritoneum 
    Lung 
 
 
340 (46%) 
41 (5%) 
136 (16%) 
 
46 (35%) 
4 (3%) 
18 (14%) 
 
386 (40%) 
45 (4.5%) 
154 (16%) 
* PS unknown or 3 in < 1% of all patients 
** Data was unavailable for one patient in the SCC group
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Table 2: Multivariate analyses of overall survival 
 Univariate analysis Multivariate analysis 
Factors HR 95% CI 
P 
value 
HR 95% CI P value 
Overall survival       
Histological 
Arm 
Adenocarcinoma 
(r) 
1.000      
SCC 1.196 0.972 – 1.471 0.089    
Sex 
Female (r) 1.000      
Male 0.983 0.807 – 1.196 0.983    
Subsite 
Oesophagus (r) 1.000      
OGJ 0.988 0.853 – 1.145 0.876    
Liver Mets 
No (r) 1.000   1.000   
Yes 1.671 1.433 – 1.948 <0.001 1.581 1.341 – 1.863 <0.001 
Peritoneal Mets 
No (r) 1.000   1.000   
Yes 2.290 1.583 – 3.314 <0.01 2.190 1.503 – 3.191 <0.001 
ALP 
<100U/I (r) 1.000   1.000   
≥100U/I 1.608 1.357 – 1.908 <0.001 1.287 1.072 – 1.544 0.007 
Performance 
Score 
0 – 1 (r) 1.000   1.000   
2 - 3 2.140 1.754 – 2.611 <0.001 1.703 1.374 – 2.110 <0.001 
Treatment Arm 
EOX (r) 1.000      
EOF 1.122 0.848 – 1.484 0.420    
ECX 1.139 0.862 – 1.505 0.361    
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ECF 1.175 0.916 – 1.506 0.204    
MCF 1.176 0.870 – 1.589 0.291    
PVI 5FU + MMC 2.107 1.461 – 3.040 <0.001    
PVI 5FU 2.132 1.481 – 3.067 <0.001    
 Overall   <0.001    
Study 
Trial 310 (r) 1.000   1.000   
Trial 115 0.993 0.804 – 1.228 0.951 1.034 0.830 – 1.288 0.763 
Trial 216 1.850 1.432 – 2.390 <0.001 1.736 1.326 – 2.271 <0.001 
 Overall   <0.001   <0.001 
All variables with a p-value of less than 0.2 in univariate analyses were entered into a multivariate model in a forward stepwise manner; 
r=reference, mets=metastases
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Table 3: Objective response rates and toxicity composite endpoint 
 
 Adeno 
 
SCC 
Number of patients 
 
841 132 
Complete response 
 
48 (6%) 7 (5%) 
Partial Response 
 
323 (38%) 36 (27%) 
Stable disease 
 
224 (30%) 35 (27%) 
Progressive disease 
 
157 (19%) 38 (29%) 
Objective response rate  
(95% CI) 
371 (44%) 
41-48% 
43 (33%) 
25-41% 
p=0.01 
Toxicity composite endpoint  
(95% CI) 
381 (45%) 
42 – 49% 
 
58 (44%) 
35 – 53% 
p=0.77 
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Figure 1:  Analysis profile  
 
 
Total Randomised n=1836 
Trial 1
15 
ECF vs. MCF 
N=580 
Adeno n=475 
SCC n=40  
 
Trial 2
16 
PVI 5-FU vs. PVI 5-FU + MMC 
N=254 
Adeno n=227 
SCC n=11 
 
Trial 3
10 
ECF vs. ECX, EOF, EOX 
N=1002 
Adeno n=885 
SCC n=101 
 
Eligible patients who received > one cycle of 
chemotherapy n=973 
Adeno 
N= 841 
SCC 
N= 132 
Patients excluded from the 
analysis: 
 
- Gastric carcinoma: n=707 
- Ineligible or withdrawn before 
treatment n=42 
-  Undifferentiated or other 
histology:  n=46* 
- Histology not recorded n= 44 
- Other (n=24) 
 
 
* Includes carcinoma, undifferentiated carcinoma, adenosquamous carcinoma 
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Figure 1 Legend 
 
CONSORT diagram indicating the derivation of eligible patients in this 
analysis. 
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Figure 2: Overall survival  
 
A According to histology (all patients) 
 
 
 
 
 
 
 
 
 
 
 
 
 
B According to histology (excluding OGJ tumours)  
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Figure 2 Legend 
A Overall survival according to histology (adenocarcinoma=841 patients, SCC 
= 132 patients). The HR for death in the adenocarcinoma group compared to 
the SCC group was 0.85 (95% CI 0.70-1.03, p=0.09) 
B Overall survival according to histology excluding OGJ tumours 
(adenocarcinoma= 438 patients, SCC= 117 patients). The HR for death for the 
adenocarcinoma group compared to the SCC group was 0.91 (95% CI 0.73-
1.13, p=0.38) 
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Figure 3: Time to developing toxicity composite endpoint (TCE) according 
histology 
 
 
 
 
 
Figure 3 Legend 
 
The time to development of the Toxicity Composite Endpoint (TCE) is shown 
for patients with adenocarcinoma (n=841) versus SCC (n=132).  
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